The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Hepcidin is considered to play a central role in the pathophysiology of renal anemia.

Who Took Part

Patients with CKD stage G3-G4 included in a double blind, randomized, placebo (PBO) controlled study with available hepcidin measurements were analyzed.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The researchers evaluated the change in markers of hepcidin expression, erythropoiesis, and iron status from baseline to week 12 and compared the change between the groups.

What Was Measured

Topics PubMed links to this paper include Hepcidins, Erythropoiesis, Vitamins, Vitamin D, Iron, Cholecalciferol and Renal Insufficiency, Chronic.

The authors tagged it with the keywords Anemia and Chronic kidney disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (BMC nephrology), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.